Guggenheim analyst Vamil Divan maintained a Buy rating on Pfizer (PFE – Research Report) yesterday. The company’s shares closed yesterday at ...

Pause for a moment. Close your eyes, and rewind to 2020. It was on the evening of 11 March, five years ago, that the Covid-19 ...

Under normal circumstances, the study of health problems after COVID vaccinations posted online on Feb. 25 might not have ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

Another recent federal study, published in the journal JAMA Pediatrics in February, showed approximately 1.01 million ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as ...

It has been five years since the world was blown into the tumult of a lethal pandemic. Back then, deserted streets and ...

Freshfields represented Moderna, while Taylor Wessing advised BioNTech and Munich IP-firm df-mp was counsel to Pfizer.

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...